{"prompt": "['FLUAD vs Fluzone-HD', 'Version 5.0', 'September 25, 2018', 'Safety and Immunogenicity of Adjuvanted versus High-Dose Inactivated Influenza Vaccines in', 'Older Adults', 'Short Title: FLUADR VS. FluzoneR High-Dose Study', 'Centers for Disease Control & Prevention', 'Clinical Immunization Safety Assessment (CISA) Project', 'Lead Site (Duke University) Principal Investigator: Ken Schmader, MD', 'Lead Site Sub-principal Investigator: Emmanuel B. Walter, MD, MPH', 'Contributing Site (Boston University) Principal Investigator: Elizabeth Barnett, MD', 'Contributing Site Sub-principal Investigator: Christine Liu, MD', 'Contributing Site Sub-principal Investigator: Heidi Auerbach, MD', \"Contributing Site (Cincinnati Children's Hospital Medical Center) Principal Investigator:\", 'Elizabeth Schlaudecker, MD', 'Contributing Site Sub-principal Investigator: Mary Staat, MD', 'Centers for Disease Control and Prevention (CDC) Principal Investigator: Theresa Harrington,', 'MD, MPH&TM', 'CDC Sub-principal Investigator: Karen R. Broder, MD', 'NCT # NCT03183908', 'Version Number: 5.0', '25 September 2018', '1']['FLUAD vs Fluzone-HD', 'Version 5.0', 'September 25, 2018', 'STATEMENT OF COMPLIANCE', 'This trial will be conducted in compliance with the protocol, the International Conference', 'on Harmonization (ICH) Guideline E6-Good Clinical Practice (GCP), and the applicable', 'guidelines and regulatory requirements from the United States (US) Code of Federal', 'Regulations (CFR), 45 CFR Part 46.', 'All study personnel with subject contact have completed Human Subjects Protection', 'Training.', '2']['FLUAD vs Fluzone-HD', 'Version 5.0', 'September 25, 2018', 'TABLE OF CONTENTS', 'PROTOCOL SUMMARY', '5', '1', 'BACKGROUND', '10', '1.1', 'Background', '10', '1.2', 'Summary and Rationale', '11', '2', 'STUDY OBJECTIVES AND OUTCOME MEASURES', '11', '2.1', 'Study Objectives', '11', '2.1.1', 'Primary Objectives:', '11', '2.1.2', 'Secondary Objectives', '12', '2.1.3', 'Exploratory Objectives:', '12', '2.2', 'Study Outcome Measures', '12', '2.2.1', 'Primary Outcome Measures:', '12', '2.2.2', 'Secondary Outcome Measures', '13', '2.2.3', 'Exploratory Outcome Measures', '13', '3', 'STUDY DESIGN', '14', '3.1', 'Main study design', '14', '3.2', 'Laboratory Studies', '14', '4', 'STUDY ENROLLMENT AND WITHDRAWAL', '15', '4.1', 'Subject Inclusion Criteria', '15', '4.2', 'Subject Exclusion Criteria', '15', '4.3', 'Recruitment', '16', '4.4', 'Reasons for and Handling of Withdrawals', '18', '4.5', 'Termination of Study', '18', '5', 'STUDY SCHEDULE, PROCEDURES, & EVLAUTIONS', '18', '5.1', 'Schedule of events and data collection', '18', '5.2.1 Randomization', '22', '5.3', 'Data Collection', '23', '5.3.1 Vaccine Supply, Storage, Administration, and Blinding', '23', '5.4', 'Reactogenicity and Safety Assessment', '24', '5.4.2', 'Reporting of Adverse Events', '27', '5.4.3', 'Safety Monitoring Plan', '28', '5.5', 'Health-Related Quality of Life (HRQOL)', '28', '5.5.1', 'Generic Measures of HRQOL', '28', '5.5.2', 'Vaccination Specific Measure of HRQOL', '30', '5.5.3 Perceptions of the Vaccination Experience and Methods of Adverse Event', 'Monitoring', '30', '5.6', 'Health Care Utilization', '30', '5.7', 'Biospecimens Collection & Handling', '30', '5.7.1 Serum', '30', '6', 'LABORATORY ANALYSES', '31', '3']\n\n###\n\n", "completion": "END"}